 Carlos Catalano
Concepts (253)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Bacteriophage lambda | 52 | 2025 | 88 | 10.270 |
Why?
| | Virus Assembly | 36 | 2025 | 78 | 8.490 |
Why?
| | DNA, Viral | 36 | 2025 | 364 | 5.150 |
Why?
| | DNA Packaging | 18 | 2025 | 24 | 5.120 |
Why?
| | Endodeoxyribonucleases | 32 | 2025 | 72 | 4.400 |
Why?
| | Genome, Viral | 17 | 2020 | 144 | 3.650 |
Why?
| | Capsid Proteins | 10 | 2022 | 94 | 3.240 |
Why?
| | Capsid | 14 | 2022 | 93 | 3.020 |
Why?
| | Viral Proteins | 21 | 2019 | 342 | 2.570 |
Why?
| | Integration Host Factors | 10 | 2025 | 13 | 1.650 |
Why?
| | Nanoparticles | 4 | 2022 | 481 | 1.600 |
Why?
| | Adenosine Triphosphate | 17 | 2020 | 491 | 1.360 |
Why?
| | Glycoproteins | 5 | 2017 | 342 | 1.290 |
Why?
| | Molecular Motor Proteins | 5 | 2011 | 45 | 1.090 |
Why?
| | Adenosine Triphosphatases | 14 | 2019 | 168 | 1.000 |
Why?
| | Protein Folding | 8 | 2022 | 280 | 0.840 |
Why?
| | Escherichia coli | 11 | 2025 | 815 | 0.740 |
Why?
| | Hydrolysis | 11 | 2019 | 177 | 0.730 |
Why?
| | Models, Molecular | 12 | 2017 | 1570 | 0.720 |
Why?
| | Thermodynamics | 6 | 2015 | 407 | 0.700 |
Why?
| | Breast Neoplasms | 2 | 2022 | 2253 | 0.620 |
Why?
| | Biological Products | 1 | 2022 | 216 | 0.610 |
Why?
| | DNA-Binding Proteins | 10 | 2005 | 1502 | 0.510 |
Why?
| | Protein Precursors | 1 | 2017 | 134 | 0.500 |
Why?
| | HIV Envelope Protein gp160 | 1 | 2015 | 5 | 0.490 |
Why?
| | Nucleic Acid Conformation | 5 | 2015 | 728 | 0.480 |
Why?
| | DNA Helicases | 3 | 2011 | 145 | 0.480 |
Why?
| | AIDS Vaccines | 1 | 2015 | 52 | 0.470 |
Why?
| | Molecular Sequence Data | 13 | 2013 | 2900 | 0.420 |
Why?
| | Kinetics | 16 | 2012 | 1670 | 0.380 |
Why?
| | Trastuzumab | 2 | 2022 | 96 | 0.360 |
Why?
| | Escherichia coli Proteins | 2 | 2020 | 200 | 0.360 |
Why?
| | Catalysis | 7 | 2019 | 307 | 0.360 |
Why?
| | DNA | 6 | 2024 | 1459 | 0.340 |
Why?
| | DNA Viruses | 2 | 2012 | 14 | 0.340 |
Why?
| | Protein Subunits | 4 | 2006 | 239 | 0.340 |
Why?
| | Protein Multimerization | 3 | 2017 | 192 | 0.340 |
Why?
| | Amino Acid Sequence | 9 | 2013 | 2139 | 0.340 |
Why?
| | Protein Structure, Quaternary | 5 | 2019 | 128 | 0.330 |
Why?
| | Ultracentrifugation | 4 | 2017 | 52 | 0.320 |
Why?
| | Peptide Hydrolases | 1 | 2010 | 111 | 0.310 |
Why?
| | Protein Conformation | 9 | 2014 | 934 | 0.310 |
Why?
| | Bacteriophages | 2 | 2024 | 98 | 0.310 |
Why?
| | Nucleotides | 2 | 2008 | 125 | 0.300 |
Why?
| | Nucleocapsid | 1 | 2008 | 19 | 0.300 |
Why?
| | Nucleoproteins | 3 | 2019 | 27 | 0.290 |
Why?
| | Promoter Regions, Genetic | 4 | 2017 | 1250 | 0.290 |
Why?
| | DNA Replication | 3 | 2006 | 238 | 0.270 |
Why?
| | Models, Biological | 6 | 2015 | 1783 | 0.270 |
Why?
| | Protein Structure, Secondary | 4 | 2017 | 374 | 0.250 |
Why?
| | Mutation | 8 | 2019 | 3958 | 0.250 |
Why?
| | Biological Assay | 1 | 2006 | 124 | 0.240 |
Why?
| | DNA, Bacterial | 1 | 2006 | 337 | 0.230 |
Why?
| | Holoenzymes | 1 | 2005 | 24 | 0.230 |
Why?
| | Chest Pain | 1 | 2025 | 91 | 0.230 |
Why?
| | Proteomics | 2 | 2022 | 1111 | 0.230 |
Why?
| | Hydrophobic and Hydrophilic Interactions | 2 | 2017 | 187 | 0.210 |
Why?
| | Cell Line, Tumor | 2 | 2022 | 3412 | 0.210 |
Why?
| | Delayed-Action Preparations | 1 | 2024 | 181 | 0.210 |
Why?
| | Binding Sites | 7 | 2016 | 1303 | 0.200 |
Why?
| | Ubiquitin-Specific Peptidase 7 | 1 | 2022 | 4 | 0.200 |
Why?
| | Dimerization | 4 | 2005 | 199 | 0.200 |
Why?
| | GTP Phosphohydrolases | 2 | 2000 | 93 | 0.190 |
Why?
| | Radiology | 1 | 2025 | 180 | 0.190 |
Why?
| | Models, Chemical | 1 | 2004 | 263 | 0.190 |
Why?
| | Temperature | 4 | 2024 | 679 | 0.190 |
Why?
| | Protein Stability | 2 | 2013 | 176 | 0.180 |
Why?
| | Adenine Nucleotides | 1 | 2020 | 23 | 0.170 |
Why?
| | Acid Anhydride Hydrolases | 1 | 1999 | 6 | 0.160 |
Why?
| | Base Sequence | 7 | 2000 | 2181 | 0.160 |
Why?
| | AAA Domain | 1 | 2019 | 3 | 0.160 |
Why?
| | DNA Polymerase I | 2 | 1990 | 29 | 0.160 |
Why?
| | Cations, Divalent | 2 | 2012 | 52 | 0.160 |
Why?
| | Circular Dichroism | 4 | 2001 | 149 | 0.160 |
Why?
| | Bacterial Proteins | 5 | 2013 | 879 | 0.150 |
Why?
| | Receptor, ErbB-2 | 1 | 2021 | 341 | 0.150 |
Why?
| | Sodium Chloride | 2 | 2015 | 142 | 0.150 |
Why?
| | Protein Domains | 2 | 2017 | 289 | 0.140 |
Why?
| | Nuclear Magnetic Resonance, Biomolecular | 3 | 2011 | 340 | 0.140 |
Why?
| | Protein Structure, Tertiary | 4 | 2010 | 861 | 0.140 |
Why?
| | Phosphates | 1 | 2019 | 182 | 0.140 |
Why?
| | Plasmids | 3 | 2014 | 363 | 0.140 |
Why?
| | Arginine | 1 | 2019 | 271 | 0.140 |
Why?
| | Substrate Specificity | 4 | 2013 | 372 | 0.140 |
Why?
| | Sequence Deletion | 3 | 2005 | 183 | 0.130 |
Why?
| | Glutamic Acid | 1 | 2019 | 246 | 0.130 |
Why?
| | Static Electricity | 1 | 2017 | 118 | 0.130 |
Why?
| | Carotid Artery Diseases | 1 | 2016 | 64 | 0.130 |
Why?
| | Vaccines | 1 | 2022 | 406 | 0.130 |
Why?
| | Peptide Fragments | 2 | 1999 | 706 | 0.130 |
Why?
| | Area Under Curve | 1 | 2017 | 314 | 0.130 |
Why?
| | Lipase | 1 | 2016 | 69 | 0.130 |
Why?
| | Molecular Weight | 3 | 2006 | 335 | 0.130 |
Why?
| | Biomechanical Phenomena | 2 | 2017 | 810 | 0.130 |
Why?
| | Molecular Dynamics Simulation | 2 | 2019 | 213 | 0.120 |
Why?
| | Protein Binding | 5 | 2015 | 2224 | 0.120 |
Why?
| | Magnesium | 2 | 2012 | 156 | 0.120 |
Why?
| | RNA Nucleotidyltransferases | 1 | 1995 | 21 | 0.120 |
Why?
| | Acrolein | 1 | 1995 | 23 | 0.120 |
Why?
| | DNA Polymerase II | 1 | 1995 | 37 | 0.120 |
Why?
| | Italy | 2 | 2025 | 110 | 0.120 |
Why?
| | Protein Denaturation | 3 | 2001 | 74 | 0.120 |
Why?
| | Microscopy, Electron | 1 | 2015 | 443 | 0.120 |
Why?
| | Enzyme Stability | 3 | 1999 | 70 | 0.110 |
Why?
| | Electrophoretic Mobility Shift Assay | 1 | 2014 | 86 | 0.110 |
Why?
| | Genes, Bacterial | 1 | 2014 | 164 | 0.110 |
Why?
| | Biotechnology | 1 | 2014 | 42 | 0.110 |
Why?
| | Hydrogen-Ion Concentration | 2 | 2006 | 560 | 0.110 |
Why?
| | Bacterial Secretion Systems | 1 | 2013 | 6 | 0.110 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 2 | 2010 | 345 | 0.100 |
Why?
| | Cloning, Molecular | 3 | 1999 | 534 | 0.100 |
Why?
| | Validation Studies as Topic | 1 | 2013 | 22 | 0.100 |
Why?
| | Hemolysin Proteins | 1 | 2013 | 34 | 0.100 |
Why?
| | Herpesvirus 1, Human | 1 | 2014 | 87 | 0.100 |
Why?
| | Non-alcoholic Fatty Liver Disease | 1 | 2016 | 279 | 0.100 |
Why?
| | Lipid Metabolism | 1 | 2016 | 518 | 0.100 |
Why?
| | Antibodies, Neutralizing | 1 | 2015 | 286 | 0.100 |
Why?
| | Sequence Homology, Amino Acid | 2 | 2010 | 385 | 0.100 |
Why?
| | Buffers | 2 | 2006 | 56 | 0.100 |
Why?
| | Recombinant Proteins | 3 | 2005 | 1353 | 0.100 |
Why?
| | Drug Carriers | 1 | 2013 | 128 | 0.100 |
Why?
| | Ligands | 1 | 2014 | 664 | 0.100 |
Why?
| | Cross-Linking Reagents | 1 | 2013 | 217 | 0.100 |
Why?
| | Gene Expression Regulation, Bacterial | 1 | 2014 | 328 | 0.100 |
Why?
| | Spectrometry, Fluorescence | 2 | 2005 | 168 | 0.100 |
Why?
| | Bacillus Phages | 1 | 2011 | 2 | 0.090 |
Why?
| | Urea | 1 | 2012 | 81 | 0.090 |
Why?
| | Gene Expression | 1 | 2017 | 1502 | 0.090 |
Why?
| | Genetic Variation | 1 | 2016 | 991 | 0.090 |
Why?
| | Lysine | 1 | 2013 | 294 | 0.090 |
Why?
| | Binding, Competitive | 2 | 2015 | 202 | 0.090 |
Why?
| | Adenoviridae | 1 | 2011 | 193 | 0.090 |
Why?
| | Polyamines | 2 | 2006 | 40 | 0.090 |
Why?
| | Pseudomonas aeruginosa | 1 | 2013 | 352 | 0.090 |
Why?
| | DNA Primers | 3 | 2001 | 515 | 0.080 |
Why?
| | DNA Probes | 1 | 1990 | 60 | 0.080 |
Why?
| | Membrane Proteins | 1 | 2016 | 1164 | 0.080 |
Why?
| | Mass Spectrometry | 1 | 2013 | 739 | 0.080 |
Why?
| | Adenosine Diphosphate | 2 | 2009 | 79 | 0.080 |
Why?
| | Optical Tweezers | 2 | 2025 | 21 | 0.080 |
Why?
| | Humans | 9 | 2025 | 137585 | 0.080 |
Why?
| | Proteins | 1 | 2015 | 1009 | 0.080 |
Why?
| | Fluorescent Dyes | 1 | 1990 | 321 | 0.070 |
Why?
| | Muramidase | 2 | 2022 | 78 | 0.070 |
Why?
| | Liver | 1 | 2016 | 1943 | 0.070 |
Why?
| | Virion | 1 | 2008 | 93 | 0.070 |
Why?
| | Spectrophotometry, Ultraviolet | 2 | 2001 | 86 | 0.070 |
Why?
| | Azides | 2 | 2005 | 46 | 0.070 |
Why?
| | Fluorescence | 1 | 2007 | 160 | 0.070 |
Why?
| | Magnetic Resonance Spectroscopy | 2 | 2016 | 611 | 0.070 |
Why?
| | Female | 4 | 2022 | 73304 | 0.060 |
Why?
| | Virulence | 1 | 2007 | 267 | 0.060 |
Why?
| | Biophysical Phenomena | 2 | 2007 | 64 | 0.060 |
Why?
| | Acrylamide | 1 | 2005 | 3 | 0.060 |
Why?
| | Photoaffinity Labels | 1 | 2005 | 6 | 0.060 |
Why?
| | Energy Metabolism | 1 | 2011 | 922 | 0.060 |
Why?
| | Biophysics | 2 | 2007 | 71 | 0.060 |
Why?
| | Macromolecular Substances | 2 | 1998 | 229 | 0.060 |
Why?
| | Single Molecule Imaging | 1 | 2025 | 37 | 0.060 |
Why?
| | Phage Therapy | 1 | 2024 | 15 | 0.060 |
Why?
| | Bone Cements | 1 | 2024 | 43 | 0.050 |
Why?
| | Computed Tomography Angiography | 1 | 2025 | 129 | 0.050 |
Why?
| | Vanadates | 1 | 2004 | 14 | 0.050 |
Why?
| | Drug Compounding | 1 | 2024 | 101 | 0.050 |
Why?
| | Tryptophan | 1 | 2005 | 183 | 0.050 |
Why?
| | Coronary Angiography | 1 | 2025 | 317 | 0.050 |
Why?
| | Protein Isoforms | 1 | 2005 | 404 | 0.050 |
Why?
| | Climate Change | 1 | 2025 | 183 | 0.050 |
Why?
| | Helix-Turn-Helix Motifs | 1 | 2002 | 5 | 0.050 |
Why?
| | Acute Disease | 1 | 2025 | 1007 | 0.050 |
Why?
| | Consensus | 1 | 2025 | 683 | 0.050 |
Why?
| | Adenosine | 1 | 2004 | 225 | 0.050 |
Why?
| | Aluminum Oxide | 1 | 2022 | 13 | 0.050 |
Why?
| | Powders | 1 | 2022 | 43 | 0.050 |
Why?
| | Models, Genetic | 1 | 2005 | 600 | 0.050 |
Why?
| | False Negative Reactions | 1 | 2021 | 53 | 0.040 |
Why?
| | Societies, Medical | 1 | 2025 | 820 | 0.040 |
Why?
| | Structure-Activity Relationship | 1 | 2002 | 570 | 0.040 |
Why?
| | HIV Infections | 1 | 2015 | 2836 | 0.040 |
Why?
| | Nitrogen Isotopes | 1 | 2000 | 72 | 0.040 |
Why?
| | Image Processing, Computer-Assisted | 1 | 2005 | 752 | 0.040 |
Why?
| | Genes, Viral | 3 | 1997 | 88 | 0.040 |
Why?
| | Protons | 1 | 2000 | 89 | 0.040 |
Why?
| | Nucleoside-Triphosphatase | 1 | 1999 | 6 | 0.040 |
Why?
| | Carbon Isotopes | 1 | 2000 | 144 | 0.040 |
Why?
| | Guanosine Triphosphate | 1 | 1999 | 91 | 0.040 |
Why?
| | Allosteric Regulation | 1 | 1999 | 97 | 0.040 |
Why?
| | Endonucleases | 1 | 1999 | 32 | 0.040 |
Why?
| | Histidine | 1 | 1999 | 64 | 0.040 |
Why?
| | Catalytic Domain | 1 | 1999 | 207 | 0.040 |
Why?
| | Gene Expression Regulation, Viral | 1 | 1999 | 95 | 0.040 |
Why?
| | Sarcosine | 1 | 1998 | 10 | 0.040 |
Why?
| | Guanidine | 1 | 1998 | 21 | 0.040 |
Why?
| | Detergents | 1 | 1998 | 44 | 0.040 |
Why?
| | Hot Temperature | 1 | 2001 | 391 | 0.040 |
Why?
| | Solutions | 1 | 1998 | 168 | 0.040 |
Why?
| | Solubility | 1 | 1998 | 245 | 0.040 |
Why?
| | Pseudomonas Phages | 1 | 1997 | 3 | 0.030 |
Why?
| | Terminator Regions, Genetic | 1 | 1997 | 12 | 0.030 |
Why?
| | Suppression, Genetic | 1 | 1997 | 25 | 0.030 |
Why?
| | Imidazoles | 1 | 1998 | 238 | 0.030 |
Why?
| | Carotid Artery, Common | 1 | 2016 | 36 | 0.030 |
Why?
| | Carotid Intima-Media Thickness | 1 | 2016 | 90 | 0.030 |
Why?
| | Asymptomatic Diseases | 1 | 2016 | 89 | 0.030 |
Why?
| | Iodoacetamide | 1 | 1995 | 5 | 0.030 |
Why?
| | Dithiothreitol | 1 | 1995 | 17 | 0.030 |
Why?
| | DNA Primase | 1 | 1995 | 47 | 0.030 |
Why?
| | Oligodeoxyribonucleotides | 1 | 1995 | 143 | 0.030 |
Why?
| | Point Mutation | 1 | 2016 | 235 | 0.030 |
Why?
| | Vero Cells | 1 | 2014 | 69 | 0.030 |
Why?
| | Anti-Bacterial Agents | 1 | 2024 | 1809 | 0.030 |
Why?
| | Receptors, Transferrin | 1 | 2013 | 24 | 0.030 |
Why?
| | Emergency Service, Hospital | 1 | 2025 | 2069 | 0.030 |
Why?
| | Microscopy, Atomic Force | 1 | 2014 | 126 | 0.030 |
Why?
| | Transferrin | 1 | 2013 | 47 | 0.030 |
Why?
| | Virus Internalization | 1 | 2013 | 49 | 0.030 |
Why?
| | Prognosis | 1 | 2022 | 4030 | 0.030 |
Why?
| | Amidohydrolases | 1 | 2013 | 31 | 0.030 |
Why?
| | Restriction Mapping | 1 | 1993 | 77 | 0.030 |
Why?
| | Chromatography, Ion Exchange | 1 | 1993 | 55 | 0.030 |
Why?
| | Chromatography, Affinity | 1 | 1993 | 88 | 0.030 |
Why?
| | Ultrasonography | 1 | 2016 | 759 | 0.020 |
Why?
| | Materials Testing | 1 | 2014 | 356 | 0.020 |
Why?
| | Viral Plaque Assay | 1 | 2011 | 31 | 0.020 |
Why?
| | HeLa Cells | 1 | 2013 | 636 | 0.020 |
Why?
| | Tomography, X-Ray Computed | 1 | 2022 | 2691 | 0.020 |
Why?
| | Molecular Chaperones | 1 | 2013 | 195 | 0.020 |
Why?
| | Predictive Value of Tests | 1 | 2016 | 2031 | 0.020 |
Why?
| | Tandem Mass Spectrometry | 1 | 2013 | 532 | 0.020 |
Why?
| | Bacteriophage T4 | 1 | 2010 | 15 | 0.020 |
Why?
| | Computer Graphics | 1 | 1990 | 42 | 0.020 |
Why?
| | Microspheres | 1 | 2010 | 137 | 0.020 |
Why?
| | Amino Acid Motifs | 1 | 2010 | 225 | 0.020 |
Why?
| | Viral Load | 1 | 2011 | 466 | 0.020 |
Why?
| | Exodeoxyribonuclease V | 1 | 1989 | 6 | 0.020 |
Why?
| | Exodeoxyribonucleases | 1 | 1989 | 22 | 0.020 |
Why?
| | Lung | 1 | 2022 | 4060 | 0.020 |
Why?
| | Phenotype | 1 | 2016 | 3196 | 0.020 |
Why?
| | Genetic Predisposition to Disease | 1 | 2016 | 2426 | 0.020 |
Why?
| | Algorithms | 1 | 2015 | 1704 | 0.020 |
Why?
| | Risk Assessment | 1 | 2016 | 3457 | 0.020 |
Why?
| | Adult | 2 | 2021 | 37929 | 0.020 |
Why?
| | Magnetic Resonance Imaging | 1 | 2016 | 3566 | 0.010 |
Why?
| | Microscopy, Fluorescence | 1 | 2005 | 402 | 0.010 |
Why?
| | Risk Factors | 1 | 2016 | 10388 | 0.010 |
Why?
| | DNA, Recombinant | 1 | 2001 | 47 | 0.010 |
Why?
| | Virus Replication | 1 | 2001 | 483 | 0.010 |
Why?
| | Trypsin | 1 | 1997 | 77 | 0.010 |
Why?
| | Affinity Labels | 1 | 1996 | 26 | 0.010 |
Why?
| | Mutagenesis, Site-Directed | 1 | 1996 | 375 | 0.010 |
Why?
| | Middle Aged | 1 | 2016 | 33479 | 0.010 |
Why?
| | Animals | 1 | 2014 | 36940 | 0.010 |
Why?
| | Male | 1 | 2016 | 67762 | 0.000 |
Why?
|
|
Catalano's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|